Evidence map›Paper›PMID 25703548›Full record

ArticleImmunological reviews2015

What can immunology contribute to the control of the world's leading cause of death from bacterial infection?

Carl Nathan

Abstract readEditorial
In one paragraph

Article in Immunological reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Striking the right immunological balance prevents progression of tuberculosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Carl NathanDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.

Funding

Viable but Nonculturable MtbU19AI111143 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI GLICKMAN, MICHAEL S, RHEE, KYU Y · 2014 to 2020
$48.6M
Targets in Mycobacterium Tuberculosis: Stress Resistance & RepairR01AI064768 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI NATHAN, CARL FRANCIS · 2005 to 2015
$8.6M
Targeting the Host to Treat TB: Inhibitors of Protein Kinase RR33AI105807 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI NATHAN, CARL FRANCIS · 2015 to 2017
$1.1M
Targeting the Host to Treat TB: Inhibitors of Protein Kinase RR21AI105807 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI NATHAN, CARL FRANCIS · 2013 to 2014
$394k
NIAID NIH HHS R01 AI064768NIAID NIH HHS R01 AI105807NIAID NIH HHS R01 AI64768NIAID NIH HHS R21 AI105807NIAID NIH HHS R33 AI105807NIAID NIH HHS U19 AI111143
6 · The paper itself

Abstract

Video podcast available Go to www.immunologicalreviews.com to watch an interview with Guest Editor Carl Nathan.

Indexed as

Bacterial InfectionsCause of DeathHumansMycobacterium tuberculosisTuberculosis

Identifiers

PMID25703548
PMCPMC4339219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.